Analyzing Tharimmune (NASDAQ:THAR) and Aileron Therapeutics (NASDAQ:ALRN)

Tharimmune (NASDAQ:THAR) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Institutional and Insider Ownership

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by company insiders. Comparatively, 5.6% of Aileron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Tharimmune has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Tharimmune and Aileron Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	0	0	0	0	N/A
Aileron Therapeutics	0	0	1	1	3.50

Aileron Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 420.55%. Given Aileron Therapeutics’ higher possible upside, analysts clearly believe Aileron Therapeutics is more favorable than Tharimmune.

Profitability

This table compares Tharimmune and Aileron Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-144.13%	-113.57%
Aileron Therapeutics	N/A	-84.88%	-30.81%

Valuation and Earnings

This table compares Tharimmune and Aileron Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$9.32 million	N/A	N/A
Aileron Therapeutics	N/A	N/A	-$15.73 million	($3.19)	-1.14

Summary

Aileron Therapeutics beats Tharimmune on 8 of the 9 factors compared between the two stocks.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

About Aileron Therapeutics

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.